Roivant Sciences launches first solo drug, Lisraya, after FDA approval for dermatomyositis
read at BioSpace ↗ApprovalPositive
Roivant Sciences, which operates a hub-and-spoke subsidiary model, is stepping into the commercial arena with its inaugural solo product launch.
The FDA has granted approval to the oral TYK2/JAK inhibitor Lisraya for the treatment of dermatomyositis, marking the first approval for Roivant's subsidiary Priovant.
CEO Matt Gline described the period as the busiest in the company's history, noting that the launch will test the firm's ability to turn its pipeline into market success while additional milestones loom.
source
This writeup was produced by pharmadog from original reporting by BioSpace.
Original headline: “Roivant, the 'inveterate drug hunters', enters commercial era with Lisraya”
read at BioSpace ↗1,593 words · retrieved 1h ago
comments(0)
5-min edit window · permanent after that